Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) Invested Capital (2016 - 2025)

Veracyte's Invested Capital history spans 14 years, with the latest figure at $1.3 billion for Q4 2025.

  • For Q4 2025, Invested Capital rose 9.89% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $1.3 billion, up 9.89%, while the annual FY2025 figure was $1.3 billion, 9.89% up from the prior year.
  • Invested Capital for Q4 2025 was $1.3 billion at Veracyte, up from $1.3 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $1.3 billion in Q4 2025 and bottomed at $971.2 million in Q2 2021.
  • The 5-year median for Invested Capital is $1.1 billion (2021), against an average of $1.1 billion.
  • The largest annual shift saw Invested Capital soared 327.93% in 2021 before it dropped 5.21% in 2022.
  • A 5-year view of Invested Capital shows it stood at $1.1 billion in 2021, then dropped by 1.83% to $1.1 billion in 2022, then dropped by 2.75% to $1.0 billion in 2023, then rose by 13.97% to $1.2 billion in 2024, then rose by 9.89% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Invested Capital are $1.3 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.2 billion (Q2 2025).